SCHEMBL3208264

SCHEMBL3208264

O=C(O)/C=C/c1cc(O)nn1Cc1ccc(C(F)(F)F)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARG P37231 8/20 0.49
PTGDR2 Q9Y5Y4 2/20 0.45
FAAH O00519 1/20 0.40
PDE5A O76074 1/20 0.39
PDE9A O76083 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 1/20 0.38
ALDH1A1 P00352 1/20 0.38
NPC1 O15118 1/20 0.37
SLC16A3 O15427 1/20 0.37
SLC16A1 P53985 1/20 0.37
MCTS1 Q9ULC4 1/20 0.37
MRGPRX4 Q96LA9 1/20 0.37
SORT1 Q99523 1/20 0.36
ESR1 P03372 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3208276 1.00 PPARG (0.49) PPARGPTGDR2FAAHPDE5APDE9A
SCHEMBL3204752 0.87 PPARG (0.54) PPARGPTGDR2FAAHPDE5APDE9A
SCHEMBL3204742 0.87 PPARG (0.54) PPARGPTGDR2FAAHPDE5APDE9A
SCHEMBL3204459 0.86 PPARG (0.48) PPARGPTGDR2CYP1A2CYP2C9HPGD
SCHEMBL3204469 0.86 PPARG (0.48) PPARGPTGDR2CYP1A2CYP2C9HPGD
SCHEMBL3212820 0.86 NPC1 (0.52) PPARGPTGDR2FAAHNPC1SLC16A3
SCHEMBL3212803 0.86 NPC1 (0.52) PPARGPTGDR2FAAHNPC1SLC16A3
SCHEMBL3206869 0.84 PPARG (0.67) PPARGPTGDR2FAAHESR1
SCHEMBL3206852 0.84 PPARG (0.67) PPARGPTGDR2FAAHESR1
SCHEMBL3212898 0.83 PPARG (0.71) PPARGPTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041892-A1 Therapeutic agent for diabetes ABE HIDENORI 2010-02-18 US disclosed
US-20090270631-A1 Therapeutic agent for diabetes ABE HIDENORI 2009-10-29 US disclosed
EP-1912645-A2 THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2008-04-23 EP disclosed
US-20080009530-A1 Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-10 US disclosed
WO-2007018314-A2 THERAPEUTIC AGENT FOR DIABETES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270631-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 PPARG 31/4885PTGDR2 1289/4885FAAH 1354/4885
US-20080009530-A1 Therapeutic Agent for Diabetes FABP4, SLC5A1, SLC5A2 PPARG 30/4885PTGDR2 1005/4885FAAH 955/4885
US-20100041892-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 PPARG 31/4885PTGDR2 1289/4885FAAH 1354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.